Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases

Current Cardiology Reports
Parth Shah

Abstract

This review aims to explore and summarize the current literature on the cardiovascular disease (CVD) healthcare burden and determine the cost-effectiveness of the PCSK9 inhibitors. The CVD remain the largest cause of mortality in the USA presenting substantial healthcare cost burden reaching $555 billion in 2016 and projected to rise to $1.1 trillion by 2035. The PCSK9 inhibitors have shown strong efficacy in LDLC lowering, but its price of ~ 14,000-14,600 per patient per year coupled with ~ 2.2-2.8 years of cardiovascular outcome data has created many controversies surrounding its cost-effectiveness. To determine the cost-effectiveness of the PCSK9 inhibitors, various simulation models and risk-based stratification and case-by-case patient approachs have yielded divisive data which need to be reassessed as per the ODYSSEY and long-term CVD outcomes. Further studies are warranted to evaluate the long-term CVD event rates of patients on the PCSK9 inhibitors to determine its true cost-effectiveness.

References

Jan 1, 1982·Social Science & Medicine·F Haayer
Dec 5, 1998·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S AllenM Yacoub
Jan 23, 1999·The American Journal of Cardiology·S M Marcovina, M L Koschinsky
Feb 24, 2006·The American Journal of Medicine·James E Dalen
Jun 10, 2009·Circulation·Michael J PencinaRamachandran S Vasan
Jan 26, 2011·Circulation·Paul A HeidenreichUNKNOWN Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research
Jul 7, 2011·Current Medical Research and Opinion·Charles J GlueckNaila Goldenberg
Jul 27, 2011·Circulation·William S WeintraubUNKNOWN Council on Clinical Cardiology, and Stroke Council
Sep 25, 2012·Journal of Internal Medicine·F Kronenberg, G Utermann
Feb 5, 2013·Journal of the American College of Cardiology·Pia R KamstrupBørge G Nordestgaard
Mar 14, 2014·The Lancet. Diabetes & Endocrinology·Pia R Kamstrup, Børge G Nordestgaard
Mar 19, 2014·Diabetes Research and Clinical Practice·L GuariguataJ E Shaw
Dec 19, 2014·Circulation·Dariush MozaffarianUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Mar 4, 2015·Clinical Research in Cardiology Supplements·Bilgen KurtJuergen R Schaefer
Mar 17, 2015·The New England Journal of Medicine·Jennifer G RobinsonUNKNOWN ODYSSEY LONG TERM Investigators
Mar 17, 2015·The New England Journal of Medicine·Marc S SabatineUNKNOWN Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators
Sep 9, 2015·JAMA : the Journal of the American Medical Association·Andy MenkeCatherine C Cowie
Oct 18, 2015·Journal of Lipid Research·Corey A ScipioneMarlys L Koschinsky
Dec 4, 2015·MMWR. Morbidity and Mortality Weekly Report·Carla MercadoFleetwood Loustalot
Dec 8, 2015·Journal of Lipid Research·Julian C van CapelleveenErik S G Stroes
Dec 18, 2015·Circulation·UNKNOWN Writing Group MembersUNKNOWN Stroke Statistics Subcommittee
Jan 27, 2016·Circulation·UNKNOWN Writing Group MembersUNKNOWN Stroke Statistics Subcommittee
Mar 22, 2016·JAMA : the Journal of the American Medical Association·Maarten J G LeeningNorrina B Allen
Aug 18, 2016·JAMA : the Journal of the American Medical Association·Dhruv S KaziKirsten Bibbins-Domingo
Oct 28, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·Steve VarvelSotirios Tsimikas
Oct 30, 2016·The American Journal of Cardiology·Daniel GaudetFrederick J Raal
Nov 16, 2016·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

JAMA : the Journal of the American Medical Association
Fatima Rodriguez, Robert A Harrington
Journal of Thrombosis and Thrombolysis
James LatimerVijay Kunadian
Revue médicale suisse
Iveta Petrova-SlaterMarco Moccetti
Current Atherosclerosis Reports
Anandita AgarwalaSalim S Virani
Trends in Cardiovascular Medicine
James P Walsh
© 2022 Meta ULC. All rights reserved